[go: up one dir, main page]

RU2345996C1 - Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application - Google Patents

Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application Download PDF

Info

Publication number
RU2345996C1
RU2345996C1 RU2007127192/04A RU2007127192A RU2345996C1 RU 2345996 C1 RU2345996 C1 RU 2345996C1 RU 2007127192/04 A RU2007127192/04 A RU 2007127192/04A RU 2007127192 A RU2007127192 A RU 2007127192A RU 2345996 C1 RU2345996 C1 RU 2345996C1
Authority
RU
Russia
Prior art keywords
optionally substituted
substituted
alkyl
atom
general formula
Prior art date
Application number
RU2007127192/04A
Other languages
Russian (ru)
Inventor
Александр Васильевич Иващенко (US)
Александр Васильевич Иващенко
Сергей Евгеньевич Ткаченко (RU)
Сергей Евгеньевич Ткаченко
Иль Матусович Окунь (US)
Илья Матусович Окунь
Николай Филиппович Савчук (RU)
Николай Филиппович Савчук
Андрей Александрович Иващенко (RU)
Андрей Александрович Иващенко
Дмитрий Владимирович Кравченко (RU)
Дмитрий Владимирович Кравченко
Елена Александровна Рыжова (RU)
Елена Александровна Рыжова
бьев Сергей Борисович Ал (RU)
Сергей Борисович Алябьев
Александр Викторович Хват (US)
Александр Викторович Хват
Original Assignee
Андрей Александрович Иващенко
Алла Хем, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андрей Александрович Иващенко, Алла Хем, Ллс filed Critical Андрей Александрович Иващенко
Priority to RU2007127192/04A priority Critical patent/RU2345996C1/en
Priority to PCT/IB2008/052846 priority patent/WO2009010925A2/en
Application granted granted Critical
Publication of RU2345996C1 publication Critical patent/RU2345996C1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

FIELD: chemistry.
SUBSTANCE: present invention relates to new annelated azaheterocyclic amides, including a pyrimidine fragment, with the general formula 1, method of obtaining them and their application in the form of free bases or their pharmaceutically accepted salts as inhibitors of P13K kinase, in compounds with the general formula 1:
Figure 00000130
, where: X represents an oxygen atom, sulphur atom or not necessarily substituted at the nitrogen NH group, where the substitute is selected from lower alkyls and possibly a substituted aryl; Y represents an atom of nitrogen or substituted at the carbon atom CH group, where the substitute is selected from lower alkyls; Z represents an oxygen atom; R1 represents a hydrogen atom or not necessarily substituted C1-C6alkyl, or Z represents a nitrogen atom, which is together with a carbon atom, with which it is joined, form through Z and R1 annelated imidazole cycle; R2 and R3 independently from each other represent hydrogen, not necessarily substituted with C1-C6alkyl, C3-C6cycloalkyl, not necessarily substituted with phenyl, not necessarily substituted with 6-member aza-heteroaryl, under the condition, when Y represents a nitrogen atom, or R2 and R3 independently from each other represent not necessarily substituted C1-C6alkyl, not necessarily substituted with phenyl, not necessarily substituted with 5-7-member heterocycle with 1-2 heteroatoms, selected from nitrogen and oxygen, and possibly annelated with a phenyl ring, under the condition, when Y does not necessarily represent a substituted carbon atom at the CH group, and X represents an oxygen atom, sulphur atom, or R2 represents hydrogen, and R3 represents a substituted aminoC1-C6alkyl and not necessarily substituted 5-6-member aza-heterocycloalkyl, under the condition, when Y represents a group which is substituted at the CH atom, and X represents an oxygen atom, sulphur atom, or R2 represents hydrogen, and R3 represents phenyl which is not necessarily substituted, pyridyl which is not necessarily substituted, pyrimidinyl which is not necessarily substituted, under the conditions, when R1 represents a substituted aminoC1-C6alkyl, substituted C2-C3hydroxyalkyl and aza-heterocycloalkyl not necessarily substituted, Y represents a group with CH substituted, and X represents an oxygen atom, sulphur, and the substitute of the above indicated substituted alkyl, phenyl, heterocycle, pyridyl, pyrimidyl are selected from groups of hydroxyl-, cyano-groups, hydrogen, lower alkyls, possibly mono- or di-substituted lower alkyl sulfamoyl, carbamoyl, C1-C6alkoxycarbonyl, amino, mono- or di-lower alkyl-amine, N-(lower alkyl), N-(phenylC1-C6alkyl)amine, phenyl, possibly substituted with a halogen atom, C1-C6alkyl, haloid-C1-C6alkyl; phenylC1-C6alkyl, saturated or non-saturated 5-6-member heterocycle containing 1-2-heteroatoms, selected from nitrogen, oxygen and sulphur, and possible condensation with a benzene ring R4 represents hydrogen or a lower alkyl.
EFFECT: obtaining new annelated aza-heterocyclic amides, including a pyrimidine fragment, with the general formula with the possibility of their application in the form of free bases or their pharmaceutically accepted salts as inhibitors of PI3K kinase.
16 cl, 5 tbl, 5 ex

Description

Текст описания приведен в факсимильном виде.

Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
The text of the description is given in facsimile form.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109

Claims (16)

1. Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, общей формулы 1 в форме свободных оснований или фармацевтически приемлемых солей
Figure 00000110

где Х представляет собой атом кислорода, атом серы или необязательно замещенную по азоту NH группу, где заместитель выбирается из низшего алкила или возможно замещенного арила;
Y представляет собой атом азота или замещенную по атому углерода СН группу, где заместитель выбирается из низшего алкила;
Z представляет собой атом кислорода;
R1 представляет собой атом водорода или необязательно замещенный C1-С6 алкил, или
Z представляет собой атом азота, который вместе с атомом углерода, с которым он связан, образуют через Z и R1 аннелированный имидазолиновый цикл;
R2 и R3 независимо друг от друга представляют собой водород, необязательно замещенный C1-С6алкил, С3-С6ациклоалкил, необязательно замещенный фенил, необязательно замещенный 6-членный азагетероарил, при условии, когда Y представляет собой атом азота, или
R2 и R3 независимо друг от друга представляют собой необязательно замещенный C1-С6алкил, необязательно замещенный фенил, необязательно замещенный 5-7-членный гетероциклил с 1-2 гетероатомами, выбираемыми из азота и кислорода, и возможно аннелированный с фенильным кольцом, или R2 и R3 вместе с атомом азота, с которым они связаны, образуют необязательно замещенный 5-7-членный азагетероциклил, возможно конденсированный с бензольным кольцом или спироконденсированный с диоксаланом, при условии, когда Y представляет собой необязательно замещенную по атому углерода СН группу, а Х представляет собой атом кислорода, атом серы, или
R2 представляет собой водород, a R3 представляет собой замещенный аминоС1-С6алкил или необязательно замещенный 5-6-членный азагетероциклилалкил, при условии, когда Y представляет собой необязательно замещенную по атому углерода СН группу, а Х представляет собой атом кислорода, атом серы, или
R2 представляет собой водород, а R3 представляет собой необязательно замещенный фенил, необязательно замещенный пиридил, необязательно замещенный пиримидинил, при условии, когда R1 представляет собой замещенный аминоС1-С6алкил, замещенный С2-С3 гидроксиалкил или необязательно замещенный азагетероциклилалкил, Y представляет необязательно замещенную по атому углерода СН группу, а Х представляет атом кислорода, атом серы;
при этом заместители в указанных выше замещенных алкиле, фениле, гетероциклиле, пиридиле, пиримидиле выбираются из группы гидрокси, цианогруппы, галогена, низшего алкила, возможно моно- или дизамещенного низшим алкилом сульфамоила, карбамоила, С1-С6алкоксикарбонила, амино, моно- или ди-низшего алкиламина, N-(низший алкил), N-(фенилС1-С6алкил)амина, фенила, возможно замещенного атомом галогена, C1-С6алкилом, галоид-С1-С6алкилом; фенилС1-С6алкила, насыщенного или ненасыщенного 5-6-членного гетероциклила, содержащего 1-2-гетероатома, выбранных из азота, кислорода и серы, и возможно конденсированного с бензольным кольцом,
R4 представляет собой водород или низший алкил;
исключая 4,5-дигидро-6-метил-4-оксо-1-(2,4,6-трихлорфенил)-1Н-пиразоло[3,4-d]пиримидин-3-карбоксамид; 4,5-дигидро-4-оксо-1-дифенил-1Н-пиразоло[3,4-d]пиримидин-3-карбоксамид; 4,5-дигидро-4-оксо-1β-D-рибофуранозил-1Н-пиразоло3,4-пиримидин-3-карбоксамид.1. Annelated azaheterocycles comprising the pyrimidine moiety of general formula 1 in the form of free bases or pharmaceutically acceptable salts
Figure 00000110

where X represents an oxygen atom, a sulfur atom or an optionally nitrogen-substituted NH group, where the substituent is selected from lower alkyl or optionally substituted aryl;
Y represents a nitrogen atom or a CH group substituted on a carbon atom, wherein the substituent is selected from lower alkyl;
Z represents an oxygen atom;
R1 represents a hydrogen atom or optionally substituted C 1 -C 6 alkyl, or
Z represents a nitrogen atom, which, together with the carbon atom to which it is bonded, form an annelated imidazoline ring through Z and R1;
R 2 and R 3 independently of one another are hydrogen, optionally substituted C 1 -C 6 alkyl, C 3 -C 6 acycloalkyl, optionally substituted phenyl, optionally substituted 6-membered azaheteroaryl, provided that Y represents a nitrogen atom, or
R2 and R3 independently from each other are optionally substituted C 1 -C 6 alkyl, optionally substituted phenyl, optionally substituted 5-7 membered heterocyclyl with 1-2 heteroatoms selected from nitrogen and oxygen, and optionally annelated with a phenyl ring, or R 2 and R 3 together with the nitrogen atom to which they are bonded form an optionally substituted 5-7 membered azaheterocyclyl, possibly fused to a benzene ring or spirocondensed with dioxalan, provided that Y is an optionally substituted p carbon atom of the CH group and X represents an oxygen atom, a sulfur atom, or
R2 is hydrogen, and R3 is substituted aminoC 1 -C 6 alkyl or optionally substituted 5-6 membered azaheterocyclylalkyl, provided that Y is an optionally substituted carbon atom CH group, and X represents an oxygen atom, a sulfur atom , or
R2 is hydrogen, and R3 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, provided that R1 is substituted aminoC 1 -C 6 alkyl, substituted C 2 -C 3 hydroxyalkyl or optionally substituted azaheterocyclylalkyl, Y is optionally substituted at the carbon atom of the CH group, and X represents an oxygen atom, a sulfur atom;
while the substituents in the above substituted alkyl, phenyl, heterocyclyl, pyridyl, pyrimidyl are selected from the group of hydroxy, cyano, halogen, lower alkyl, possibly mono- or disubstituted by lower alkyl sulfamoyl, carbamoyl, C 1 -C 6 alkoxycarbonyl, amino, mono or di-lower alkylamine, N- (lower alkyl), N- (phenylC 1 -C 6 alkyl) amine, phenyl optionally substituted with a halogen atom, C 1 -C 6 alkyl, halogen-C 1 -C 6 alkyl; phenylC 1 -C 6 alkyl, saturated or unsaturated 5-6 membered heterocyclyl containing 1-2 heteroatoms selected from nitrogen, oxygen and sulfur, and possibly fused to a benzene ring,
R4 represents hydrogen or lower alkyl;
excluding 4,5-dihydro-6-methyl-4-oxo-1- (2,4,6-trichlorophenyl) -1H-pyrazolo [3,4-d] pyrimidine-3-carboxamide; 4,5-dihydro-4-oxo-1-diphenyl-1H-pyrazolo [3,4-d] pyrimidine-3-carboxamide; 4,5-dihydro-4-oxo-1β-D-ribofuranosyl-1H-pyrazolo-3,4-pyrimidine-3-carboxamide. 2. Соединения по п.1, представляющие собой замещенные амиды 4-оксо-3,4-дигидрофуро(или тиено)[2,3-b]пиримидин-5-карбоновых кислот общей формулы 1.1 или их фармацевтически приемлемые соли
Figure 00000111

где R1 и Z имеют вышеуказанные значения; X1 представляет собой атом кислорода, атом серы; R2 и R3 независимо друг от друга представляют собой необязательно замещенный алкил, необязательно замещенный фенил, необязательно замещенный гетероциклил, или R2 и R3 вместе с атомом азота, с которым они связаны, образуют необязательно замещенный 5-7-членный азагетероциклил, возможно конденсированный с бензольным кольцом, или
R2 представляет собой водород, а R3 представляет собой замещенный амино C1-С6алкил или необязательно замещенный азагетероциклилалкил, или
R2 представляет собой водород, а R3 представляет собой необязательно замещенный фенил, необязательно замещенный пиридил, необязательно замещенный пиримидинил, при условии, когда R1 представляет собой замещенный аминоалкил или необязательно замещенный азагетероциклилалкил;
R5 представляет собой водород или низший алкил.2. The compounds according to claim 1, which are substituted amides of 4-oxo-3,4-dihydrofuro (or thieno) [2,3-b] pyrimidine-5-carboxylic acids of the general formula 1.1 or their pharmaceutically acceptable salts
Figure 00000111

where R1 and Z have the above meanings; X 1 represents an oxygen atom, a sulfur atom; R2 and R3 independently from each other are optionally substituted alkyl, optionally substituted phenyl, optionally substituted heterocyclyl, or R2 and R3 together with the nitrogen atom to which they are attached form an optionally substituted 5-7 membered azaheterocyclyl, possibly fused to a benzene ring , or
R2 is hydrogen, and R3 is substituted amino C 1 -C 6 alkyl or optionally substituted azaheterocyclylalkyl, or
R2 is hydrogen, and R3 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, provided that R1 is substituted aminoalkyl or optionally substituted azaheterocyclylalkyl;
R5 represents hydrogen or lower alkyl. 3. Соединения по п.2, представляющие собой замещенные амиды 4-оксо-3,4-дигидрофуро[2,3-b]пиримидин-5-карбоновых кислот общей формулы 1.1.1, замещенные амиды 4-оксо-3,4-дигидротиено[2,3-b]пиримидин-5-карбоновых кислот общей формулы 1.1.2, замещенные амиды 2,3-дигидрофуро[3,2-е]имидазо[1,2-с]пиримидин-9-карбоновых кислот 1.1.3 и замещенные амиды 2,3-дигидротиено[3,2-е]имидазо[1,2-с]пиримидин-9-карбоновых кислот 1.1.4 или их фармацевтически приемлемые соли
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115

где R1 и R5 имеют вышеуказанное значение;
R2 и R3 независимо друг от друга представляют собой необязательно замещенный C1-С6алкил, необязательно замещенный фенил, необязательно замещенный гетероциклил, или R2 и R3 вместе с атомом азота, с которым они связаны, образуют необязательно замещенный 5-7-членный азагетероциклил, возможно конденсированный с бензольным кольцом, или
R2 представляет собой водород, а R3 представляет собой замещенный амино C1-С6алкил или необязательно замещенный азагетероциклилалкил, или
R2 представляет собой водород, а R3 представляет собой необязательно замещенный фенил, необязательно замещенный пиридил, необязательно замещенный пиримидинил, при условии, когда R1 представляет собой замещенный аминоС1-С6алкил или необязательно замещенный азагетероциклилалкил;
R6 и R7 независимо друг от друга представляют собой водород.3. The compounds according to claim 2, which are substituted amides of 4-oxo-3,4-dihydrofuro [2,3-b] pyrimidine-5-carboxylic acids of the general formula 1.1.1, substituted amides of 4-oxo-3,4- dihydrothieno [2,3-b] pyrimidine-5-carboxylic acids of the general formula 1.1.2, substituted amides of 2,3-dihydrofuro [3,2-e] imidazo [1,2-c] pyrimidine-9-carboxylic acids 1.1. 3 and substituted amides of 2,3-dihydrothieno [3,2-e] imidazo [1,2-c] pyrimidine-9-carboxylic acids 1.1.4 or their pharmaceutically acceptable salts
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115

where R1 and R5 have the above meaning;
R2 and R3, independently of one another, are optionally substituted C 1 -C 6 alkyl, optionally substituted phenyl, optionally substituted heterocyclyl, or R2 and R3 together with the nitrogen atom to which they are attached form an optionally substituted 5-7 membered azaheterocyclyl, possibly condensed with a benzene ring, or
R2 is hydrogen, and R3 is substituted amino C 1 -C 6 alkyl or optionally substituted azaheterocyclylalkyl, or
R2 is hydrogen, and R3 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, provided that R1 is substituted aminoC 1 -C 6 alkyl or optionally substituted azaheterocyclylalkyl;
R6 and R7 are independently hydrogen. 4. Соединения по п.3, представляющие собой замещенные амиды 3-аминоалкил-6-метил-4-оксо-3,4-дигидрофуро[2,3-b]пиримидин-5-карбоновых кислот общей формулы 1.1.1.1, 1.1.1.2 и 1.1.1.3, замещенные амиды 3-аминоалкил-6-метил-4-оксо-3,4-дигидротиено[2,3-b]пиримидин-5-карбоновых кислот общей формулы 1.1.1.4, 1.1.1.5 и 1.1.1.6, замещенные амиды 3-гидроксиалкил-6-метил-4-оксо-3,4-дигидро-фуро[2,3-b]пиримидин-5-карбоновых кислот общей формулы 1.1.1.7 и 1.1.1.8 и замещенные амиды 3-гидроксиалкил-6-метил-4-оксо-3,4-дигидротиено[2,3-b]пиримидин-5-карбоновых кислот общей формулы 1.1.1.9 и 1.1.1.10 или их фармацевтически приемлемые соли
Figure 00000116
Figure 00000117
Figure 00000118

Figure 00000119
Figure 00000120
Figure 00000121

Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125

где R3 представляет собой необязательно замещенный фенил, необязательно замещенный пиридил, необязательно замещенный пиримидинил;
R1a и R1b независимо друг от друга представляют собой атом водорода, необязательно замещенный низший алкил или вместе с атомом углерода, с которым они связаны, образуют 5-7 членный азагетероциклил;
R1c, R1d и R1e представляют собой атом водорода или необязательно замещенный низший алкил или один из R1c, R1d и R1e вместе с атомом углерода, с которым он связан, и R1a вместе с атомом азота, с которым он связан, образуют 5-6-членный насыщенный гетероциклил с 1-2 гетероатомами, выбранными из азота и кислорода, при условии, когда два других из R1c, R1b и R1e и R1d являются водородом.4. The compounds according to claim 3, which are substituted amides of 3-aminoalkyl-6-methyl-4-oxo-3,4-dihydrofuro [2,3-b] pyrimidine-5-carboxylic acids of the general formula 1.1.1.1, 1.1. 1.2 and 1.1.1.3, substituted amides of 3-aminoalkyl-6-methyl-4-oxo-3,4-dihydrothieno [2,3-b] pyrimidine-5-carboxylic acids of the general formulas 1.1.1.4, 1.1.1.5 and 1.1. 1.6, substituted amides of 3-hydroxyalkyl-6-methyl-4-oxo-3,4-dihydro-furo [2,3-b] pyrimidine-5-carboxylic acids of the general formula 1.1.1.7 and 1.1.1.8 and substituted amides 3- hydroxyalkyl-6-methyl-4-oxo-3,4-dihydrothieno [2,3-b] pyrimidine-5-carboxylic acids of the general formulas 1.1.1.9 and 1.1.1.10 or their pharmaceutical ski acceptable salts
Figure 00000116
Figure 00000117
Figure 00000118

Figure 00000119
Figure 00000120
Figure 00000121

Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125

where R3 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidinyl;
R 1 a and R 1 b independently represent a hydrogen atom, an optionally substituted lower alkyl, or together with the carbon atom to which they are attached form 5-7 membered azaheterocyclyl;
R 1 c, R 1 d and R 1 e represent a hydrogen atom or an optionally substituted lower alkyl or one of R 1 c, R 1 d and R 1 e together with the carbon atom to which it is bonded, and R 1 a together with the nitrogen atom to which it is bonded forms a 5-6 membered saturated heterocyclyl with 1-2 heteroatoms selected from nitrogen and oxygen, provided that the other two of R 1 c, R 1 b and R 1 e and R 1 d are hydrogen. 5. Соединения по п.1, представляющие собой замещенные амиды 4-оксо-4,5-дигидро-азолопиримидин-3-карбоновых кислот общей формулы 1.2 или их фармацевтически приемлемые соли:
Figure 00000126

где R1, R4, X и Z имеют вышеуказанные значения; R2 и R3 независимо друг от друга представляют собой водород, необязательно замещенный C1-С6алкил, необязательно замещенный фенил, необязательно замещенный 6-членный азотсодержащий гетероциклил или R2 и R3 вместе с атомом азота, с которым они связаны, образуют необязательно замещенный 5-7-членный азагетероциклил.5. The compounds according to claim 1, which are substituted amides of 4-oxo-4,5-dihydro-azolopyrimidin-3-carboxylic acids of the general formula 1.2 or their pharmaceutically acceptable salts:
Figure 00000126

where R1, R4, X and Z have the above meanings; R2 and R3 independently from each other are hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted phenyl, optionally substituted 6-membered nitrogen-containing heterocyclyl, or R2 and R3 together with the nitrogen atom to which they are attached form an optionally substituted 5- 7 membered azaheterocyclyl. 6. Способ получения соединений общей формулы 1 по любому из пп.1-5 взаимодействием соответствующих кислот общей формулы F1 с аминами общей формулы F2 в присутствии конденсирующих реагентов
Figure 00000127
Figure 00000128

где X, Y, Z, R1, R2, R3 и R4 имеют вышеуказанные для соединений общей формулы 1 значения.6. A method for producing compounds of general formula 1 according to any one of claims 1 to 5 by reacting the corresponding acids of general formula F1 with amines of general formula F2 in the presence of condensing agents
Figure 00000127
Figure 00000128

where X, Y, Z, R1, R2, R3 and R4 have the above meanings for compounds of general formula 1. 7. Ингибиторы PI3 киназ, представляющие собой соединения общей формулы 1 по п.1.7. Inhibitors of PI3 kinases, which are compounds of General formula 1 according to claim 1. 8. Селективные ингибиторы изоформы р110-альфа PI3 киназ по п.7, представляющие собой соединения общей формулы 1 по п.1.8. Selective inhibitors of the isoform p110-alpha PI3 kinases according to claim 7, which are compounds of General formula 1 according to claim 1. 9. Селективные ингибиторы изоформы р110-бета PI3 киназ по п.7, представляющие собой соединения общей формулы 1 по п.1.9. Selective inhibitors of the isoform of p110-beta PI3 kinases according to claim 7, which are compounds of the general formula 1 according to claim 1. 10. Селективные ингибиторы изоформы р110-гамма PI3 киназ по п.7, представляющие собой соединения общей формулы 1 по п.1.10. Selective inhibitors of the isoform p110-gamma PI3 kinases according to claim 7, which are compounds of general formula 1 according to claim 1. 11. Селективные ингибиторы изоформы р110-дельта PI3 киназ по п.7, представляющие собой соединения общей формулы 1 по п.1.11. Selective inhibitors of the isoform p110-delta PI3 kinases according to claim 7, which are compounds of the general formula 1 according to claim 1. 12. Селективные ингибиторы изоформы р110-альфа PI3 киназ с мутацией в эксоне 20(H1047R) по п.7, представляющие собой соединения общей формулы 1 по п.1.12. Selective inhibitors of the isoform p110-alpha PI3 kinases with mutation in exon 20 (H1047R) according to claim 7, which are compounds of the general formula 1 according to claim 1. 13. Соединения общей формулы 1 по п.1, в качестве биологически активных ингредиентов для получения лекарственных средств для лечения онкологических заболеваний.13. The compounds of General formula 1 according to claim 1, as biologically active ingredients for the manufacture of medicines for the treatment of cancer. 14. Фармацевтическая композиция, обладающая свойствами ингибитора PI3 киназ, содержащая в качестве активного ингредиента, по крайней мере, одно соединение общей формулы 1 по п.1 или соединение по любому из пп.2-5 или его фармацевтически приемлемую соль в эффективном количестве.14. A pharmaceutical composition having the properties of a PI3 kinase inhibitor, containing as an active ingredient at least one compound of general formula 1 according to claim 1 or a compound according to any one of claims 2-5 or a pharmaceutically acceptable salt thereof in an effective amount. 15. Способ получения фармацевтической композиции по п.14 смешением биологически активного ингредиента по п.13 с инертным наполнителем и/или растворителем.15. The method of obtaining the pharmaceutical composition according to p. 14 by mixing the biologically active ingredient according to p. 13 with an inert filler and / or solvent. 16. Лекарственное средство в форме таблеток, капсул или инъекций, помещенных в фармацевтически приемлемую упаковку, включающее ингибитор Р13 киназ по любому из пп.7-12 или фармацевтическую композицию по п.14 в эффективном количестве. 16. A drug in the form of tablets, capsules, or injections in a pharmaceutically acceptable package, comprising the P13 kinase inhibitor according to any one of claims 7-12 or the pharmaceutical composition of claim 14 in an effective amount.
RU2007127192/04A 2007-07-17 2007-07-17 Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application RU2345996C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2007127192/04A RU2345996C1 (en) 2007-07-17 2007-07-17 Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application
PCT/IB2008/052846 WO2009010925A2 (en) 2007-07-17 2008-07-16 Annelated azaheterocyclic amides containing a pyrimidine fragment and method for the production and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2007127192/04A RU2345996C1 (en) 2007-07-17 2007-07-17 Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application

Publications (1)

Publication Number Publication Date
RU2345996C1 true RU2345996C1 (en) 2009-02-10

Family

ID=40260168

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007127192/04A RU2345996C1 (en) 2007-07-17 2007-07-17 Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application

Country Status (2)

Country Link
RU (1) RU2345996C1 (en)
WO (1) WO2009010925A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2557237C2 (en) * 2010-02-10 2015-07-20 Киссеи Фармасьютикал Ко., Лтд. Salt of condensed heterocyclic derivative and its crystals

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
GB2453058A (en) 2006-04-04 2009-03-25 Univ California Kinase antagonists
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
SG187426A1 (en) 2008-01-04 2013-02-28 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CN102124009B (en) 2008-07-08 2014-07-23 因特利凯公司 Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
EP2358720B1 (en) 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (en) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
PH12013501465A1 (en) 2011-01-10 2013-09-09 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
JP6027611B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
TW201311663A (en) 2011-08-29 2013-03-16 Infinity Pharmaceuticals Inc Heterocyclic compound and its use
JP6342805B2 (en) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Substituted pyrazolo [3,4-D] pyrimidine and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2900673A4 (en) 2012-09-26 2016-10-19 Univ California MODULATION OF IRE1
NZ708563A (en) 2012-11-01 2019-02-22 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
RS58040B1 (en) * 2012-12-21 2019-02-28 Epizyme Inc Prmt5 inhibitors and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PT3052485T (en) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2015231413B2 (en) 2014-03-19 2020-04-23 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
TWI770525B (en) 2014-12-30 2022-07-11 美商瓦洛健康公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2017281797A1 (en) 2016-06-24 2019-01-24 Infinity Pharmaceuticals, Inc. Combination therapies
RU2764243C2 (en) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Heterocyclic compounds as pad inhibitors
DK3697785T3 (en) 2017-10-18 2023-04-03 Jubilant Epipad LLC IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
JP7368369B2 (en) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Heterocyclic compounds as PRMT5 inhibitors
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
CN111281873B (en) * 2020-01-20 2021-01-26 浙江大学 DNA methyltransferase 3A inhibitor and its application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
WO2003050122A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2314224T3 (en) * 2002-03-07 2009-03-16 F. Hoffmann-La Roche Ag BIRCINAL PYRIMIDINE AND PYRIDINE INHIBITORS OF P38 QUINASA.
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
GB0520164D0 (en) * 2005-10-04 2005-11-09 Novartis Ag Organic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2557237C2 (en) * 2010-02-10 2015-07-20 Киссеи Фармасьютикал Ко., Лтд. Salt of condensed heterocyclic derivative and its crystals

Also Published As

Publication number Publication date
WO2009010925A3 (en) 2009-07-02
WO2009010925A2 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
RU2345996C1 (en) Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application
ES2697051T3 (en) Antiviral activity of bicyclic heterocycles
DK2497772T3 (en) A compound for inhibiting mitotic progression
CA2932175C (en) 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors
ES2879679T3 (en) Ultra-potent vinca alkaloids: added molecular complexity further alters the dimer-dimer interface of tubulin
TWI574691B (en) Anti - tumor agents for intermittent administration of FGFR inhibitors
RU2341527C1 (en) Annelated asaheterocycles including pyrimidine fragment, method of production thereof and pi3k kinase inhibitors
WO2018011569A1 (en) Wee-1 inhibiting pyrazolopyrimidinone compounds
CA3085346A1 (en) Amide substituted indole compounds useful as tlr inhibitors
AR038000A1 (en) COMPOSITE DERIVED FROM TIEN [2,3-D] PIRIMIDIN-2,4 (1H, 3H) -DIONA, PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARATION AND USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
ME02635B (en) Novel pyrrole derivatives, their method of preparation and pharmaceutical compositions containing them
PE20080266A1 (en) 4-AMINO-PIRIDO [3,2-E] PIRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 AND PROCESSES FOR THEIR PREPARATION
EA200501332A1 (en) DERIVATIVES OF PYRIMIDIN-4-IT AND THEIR APPLICATION AS KINAZA P38 MODULATORS
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists
IL292229A (en) Pharmacological combination of prmt5 inhibitors
RU2014152790A (en) Pyrrolopyrazone Inhibitors of Tankyrase
JP2017532360A5 (en)
JP2013533868A (en) Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and their pharmaceutical use
KR20120044281A (en) Method of treating disorders associated with protein kinase ck2 activity
RU2012102424A (en) SELECTIVE INHIBITORS Haspin KINASES
CA2619897A1 (en) Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same
WO2005040345A3 (en) 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
DOP2013000009A (en) HEREROCICLIC DERIVATIVES FUSED AS MODULATORS S1P
RU2014142633A (en) 6- (4- (1-amino-3-hydroxycyclobutyl) phenyl) -5-phenyl (furo, thieno or pyrrolo) [2,3-D] pyrimidine-4-new derivatives for the treatment of cancer
CN107459521B (en) Novel inhibitors of FLT3 kinase and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110718